Takeda will pay Insilico to use its proprietary Pharma.AI platform to advance drug candidates across several therapeutic ...

The deal could include further milestone payments, potentially bringing the total value to approximately $600m.

Alex Zhavoronkov, Founder, CEO & CBO of Insilico Medicine, says the Takeda deal lets the company scale beyond its own ...

Insilico Medicine has signed a deal worth up to $600 million with Takeda to collaborate on asset discovery across the Japan Big Pharma's therapeutic areas of interest.  | Insilico Medicine has signed ...

Insilico Medicine said Thursday it entered into a strategic collaboration with Takeda Pharmaceutical Co. Ltd. to use its ...

The pharma company, the first to use generative AI to develop a drug that reached clinical trials, is betting longevity ...

Dr. Alex Aliper, Co-founder and President of Insilico Medicine, will attend the AI for Good Global Summit 2026 in Geneva, Switzerland, on July 7.

CAMBRIDGE, Mass., July 1, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" HKEX:3696), a leader in clinical-stage generative AI for drug discovery, today announced a strategic collaboration ...

InSilico, a pioneer in AI drug discovery, aims to dominate China's pharma market while developing a groundbreaking God-like ...

New York, July 28 – Insilico Medicine, an end-to-end artificial intelligence (AI) -powered clinical-stage drug discovery and development company, announced that INS018_055, the company's first ...

A novel gut-restricted and PHD specific Inhibitor designed and optimized with the support of Insilico’s Chemistry42 commercially-available generative reinforcement learning platform, for Inflammatory ...

Insilico Medicine, a leader in clinical-stage generative AI for drug discovery, today announced a strategic collaboration agreement with Takeda to use its proprietary end-to-end platform, Pharma.AI, ...